Investigation on nesfatin-1 provided evidences that its circulating level correlated with T2DM and elevated in newly diagnostic T2DM patients (24), but decreased in those patients who received antidiabetic treatment (28). This evidence concerns the gene NUCB2 and type 2 diabetes mellitus.